Note to users.
If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more
about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Comment on "Epidermal Growth Factor Receptor Is Essential for Toll-Like Receptor 3 Signaling"
- Barbara Burtness, Shanthi Marur, Julie E. Bauman, Erica A. Golemis, Ranee Mehra, and Steven J. Cohen (11 December 2012)
Sci. Signal. 5 (254), lc5. [DOI: 10.1126/scisignal.2003734]
Targeted inhibitors used in cancer treatments may have adverse effects on immune responses.
Full Text »|
- Cell Biology
Response to Comment on "A Dynamic Network Model of mTOR Signaling Reveals TSC-Independent mTORC2 Regulation": Building a Model of the mTOR Signaling Network with a Potentially Faulty Tool
- Piero Dalle Pezze, Annika G. Sonntag, Daryl P. Shanley, and Kathrin Thedieck (10 July 2012)
Sci. Signal. 5 (232), lc4. [DOI: 10.1126/scisignal.2003224]
Dalle Pezze et al. respond to criticisms regarding the specificity of phosphorylation of Ser2481 of mTOR as a specific readout of mTORC2 activity.
Full Text »|
Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882